Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Trial Profile

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET-3; Trial 3
  • Sponsors Bausch Health Companies; Salix Pharmaceuticals; Valeant Pharmaceuticals International

Most Recent Events

  • 23 May 2021 Results (n=3837) of pooled post hoc analysis of assessing efficacy of 3 Phase III studies TARGET-1, TARGET-2 and TARGET-3, presented at the Digestive Disease Week 2021.
  • 17 May 2021 According to a Salix Pharma media release, results of pooled post hoc analysis will be presented at Digestive Disease Week (DDW) 2021.
  • 13 Oct 2020 Results of post hoc analysis assessing the subgroup of patients with a history of IBS medication use before the study presented at the 28th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top